Search Within

Ross Firestone

Formats
  1. Meeting Abstract (30)
  2. Journal Article (8)
  3. Review (3)
  4. Correspondence (1)
  5. Editorial (1)
  6. Research Letter (1)
Groups
  1. GME, Medicine (44)
  2. Graduate Medical Education (44)
  3. Hematology-Oncology Fellows (44)
  4. Weinberg Fellows (44)
  5. Department of Medicine (42)
  6. Hematologic Malignancies, Division of (41)

More Groups

People
  1. Saad Usmani (41)
  2. Kylee Maclachlan (37)
  3. Malin Hultcrantz (37)
  4. Sham Mailankody (37)
  5. Alexander Lesokhin (36)
  6. Sergio Giralt (36)

More People

Years
  1. 2025 (8)
  2. 2024 (25)
  3. 2023 (11)
Publications
  1. Blood (17)
  2. Clinical Lymphoma, Myeloma and Leukemia (13)
  3. Blood Advances (5)
  4. Blood Cancer Journal (2)
  5. Journal of Clinical Oncology (2)
  6. Blood Cancer Discovery (1)

More Publications

Publishers
  1. American Society of Hematology (23)
  2. Elsevier Inc. (14)
  3. American Association for Cancer Research (2)
  4. American Society of Clinical Oncology (2)
  5. Nature Publishing Group (2)
  6. Churchill Livingstone (1)

Results (44)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Patterns of cytokine release syndrome with teclistamab in relapsed/refractory multiple myeloma with or without prior T-cell redirection therapy
    Meeting Abstract

    Hamadeh, I.; Shekarkhand, T.; Rueda, C.; Firestone, R.; Wang, A.; Korde, N.; Hultcrantz, M.; Lesokhin, A.; Mailankody, S.; Hassoun, H.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Bispecific T-cell engager response is driven by pre-treatment CD8+ effector memory cells and inhibited by TIGIT+ Tregs in relapsed/refractory multiple myeloma
    Meeting Abstract

    Firestone, R.; McAvoy, D.; Shekarkhand, T.; Serrano, E.; Hamadeh, I.; Wang, A.; Zhu, M.; Patel, D.; Tan, C. R.; Hultcrantz, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • An embarrassment of riches: Three FDA-approved bispecific antibodies for relapsed refractory multiple myeloma
    Review

    Firestone, R.; Lesokhin, A. M.; Usmani, S. Z.
    Blood Cancer Discovery (2023)

    Fulltext@MSK | Save
  • Evaluating the efficacy of commercial teclistamab in relapsed refractory multiple myeloma patients with prior exposure to anti-BCMA therapies
    Meeting Abstract

    Firestone, R.; Shekarkhand, T.; Patel, D.; Tan, C. R. C.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Shah, U. A.; Korde, N.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save